ClinicalTrials.gg
RecruitingNCT04076449CRESSUpdated Sep 4, 2019

Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

An observational study in Cavernous Malformation, Cerebral, Cavernous Angioma and Cavernous Hemangioma, sponsored by yuanli Zhao. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-04.

Sponsored by yuanli Zhao · Observational

How we know

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Seizures with a site in China — 14 open to participants now, 16 under way, 9 of them phase 3. Seizures · China.

Planned enrollment
9th of 13
200 · median 500
Started
2019
with 1 other
Observational
13 of 39
6 open now
Primary completion
2026-12
later than 6 of 15 live
Registered
18th of 39
by date

Among the 39 studies in Seizures with a site in China, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2019, is one of 13 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 18th registered.

Seizures

766 studies on the registry are indexed under Seizures; 133 are open to participants now.

Browse Seizures studies →

Open to participants now

14 of the 39 studies in Seizures with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Seizures with a site in China, or all of them as a file.
02

Study summary

Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.

Read the detailed description

The CRESS study is a prospective observational study of imaging biomarker for cerebral cavernous malformation (CCM) related epilepsy (CRE) risk in natural history or after surgical resection. This project, funded by the National Nature Science Foundation of China, will be performed in two sites: Bejing Tiantan Hospital, Capital Medical University and Peking University International Hospital, which cover the south and north part of Beijing. Bejing Tiantan Hospital is also the China National Clinical Research Center for Neurological Diseases and the largest neurological center with high volume of patients all over the nation.

Study overview: Each participants will be followed for 5 year since enrollment. Epilepsy will be tracked with serial video EEG recordings and clinical investigations performed annually. Besides medical history of the patients, data from seizure diary and MR imaging studies (including quantitative susceptibility mapping, diffusion tensor imaging and three dimension-T1 weighted imaging), will be collected. Blood samples and tissue samples of surgical resected lesion for biomarkers studies will also be collected in all participants of the project. The data obtained in participants of CCM with or without epilepsy will be compared.

Sample size: Investigators plan to enroll 200 CCM patients in 24 months and follow up for 5 years. Based upon the preliminary results and extensive literature review, investigators predict that about 50% of participants will undergo surgical treatment, while 25% of participants remain suffering from seizure after treatment.

Study endpoints: The primary clinical endpoint of this study is a collection of a set of clinical, molecular, and MRI data in all participants.

03

Conditions studied

  • Cavernous Malformation, Cerebral
  • Cavernous Angioma
  • Cavernous Hemangioma
  • Cavernous Hemangioma of Brain
  • Seizures
  • Seizures, Epileptic
  • Epilepsy

Keywords

  • Cerebral Cavernous Malformation
  • Epilepsy
  • Quantitative Susceptibility Mapping (QSM)
  • Brain Connectome
  • Cerebral Structure
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Outpatient and inpatient referred to Beijing Tiantan Hospital and Peking University International Hospital who diagnosed with cerebral cavernous malformation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) 18 to 70 years of age
  • (2) Diagnosed with a single cerebral cavernous malformation
  • (3) No prior treatment of the symptomatic lesion

Exclusion criteria

Exclusion Criteria:

  • (1) Associated with brain lesions and/or tumors other than CCM
  • (2) History of previous intracranial surgery
  • (3) Prior brain irradiation
  • (4) or unwilling or unable to undergo research MRI studies
  • (5) Pregnant or breastfeeding women
  • (6) Persons unable or unlikely to return for follow-up visits
  • (7) Dementia or other progressive neurological disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cerebral Cavernous Malformation with Epilepsy

    Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.

  • Cerebral Cavernous Malformation without Epilepsy

    Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.

06

What researchers measure

Primary outcomes

  1. Perilesional mean QSM in CCM with conservative treatment

    Each patient contributes five outcome measurements (at annual image of 5-year follow-up). Perilesional QSM measurements will be performed at baseline and at annual epoch of image. Perilesional mean QSM (in parts per million, ppm) in each study group will be evaluated using univariate comparison and a repeated measures analysis implemented as an unadjusted linear mixed model.

    Time frame: End of study (5-year) MRI scan

  2. Perilesional mean QSM after surgical resection of CCM lesion

    Each patient contributes three outcome measurements (at year 1 and 2 and 3 after surgery). Perilesional QSM measurements will be performed at annual imaging follow-up after surgery. Mean QSM (in parts per million, ppm) in patients with or without postoperative seizure will be evaluated using univariate comparison and a repeated measures analysis implemented as an unadjusted linear mixed model.

    Time frame: End of study (3-year) MRI scan after surgery

  3. Ratio of seizure freedom during follow-up

    Seizure freedom, defined as Engel Classification of Post-treatment Outcome Class I, will be assessed annually during follow-up period. For patients with medical treatment or conservative observation, the follow-up period begins since enrollment. For patients with surgical resection, the follow-up period begins after surgery.

    Time frame: End of follow-up period (5-year)

Secondary outcomes

  1. Grey matter volume in CCM with epilepsy

    The presurgical grey matter volume will be calculated from three dimension T1 weighted imaging. Data of CCM with or without epilepsy will be compared and to detect the correlation between grey matter volume and seizure severity (Liverpool Seizure Severity Scale) and frequency.

    Time frame: End of study (5-year) MRI scan

  2. Whole-brain connectome in CCM with epilepsy

    Whole-brain connectome will be reconstructed from whole-brain diffusion tensor imaging before surgical treatment. Data of CCM with or without epilepsy will be compared.

    Time frame: End of study (5-year) MRI scan

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Ma L, Zhang S, Li Z, Wu CX, Wang Z, Zhan L, Hao Q, Wang H, Ye X, Chen X, Liu YO, Wang S, Zhao YL. Morbidity After Symptomatic Hemorrhage of Cerebral Cavernous Malformation: A Nomogram Approach to Risk Assessment. Stroke. 2020 Oct;51(10):2997-3006. doi: 10.1161/STROKEAHA.120.029942. Epub 2020 Sep 21. PubMed 32951540 ↗

Individual participant data

Plan to share: Yes — Study Protocol to be published in peer-reviewed journal

Supporting information: Study protocol

Time frame: Since the publication of study protocol

Access criteria: Available from the principle investigator upon reasonable request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Dec 2026, 87 months after the start.

Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 87 months is above that.

Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Sep 3, 2019
StartActual
Sep 3, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04076449
Lead sponsor
yuanli Zhao
Collaborators
Peking University International Hospital
Responsible party
yuanli Zhao (Professor, Department of Neurosurgery, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Sep 3, 2019
Start date
Sep 3, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 4, 2019

Study contacts

Li Ma, MD, PhD
Contact
marygl@hotmail.com
86-010-59978317
Yuanli Zhao, MD
Contact
zhaoyuanli@126.com
86-010-59978478
Li Ma, MD, PhD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion